Skip to content

Assesment of TDApp1 an eHelath Tool to Make Therapeutic Recommendations for Patients With ADHD

Development and Assesment of TDApp1 an eHelath Tool to Make Participatory, Patient-centred and Automated Therapeutic Recommendations for Patients With Attention Deficit Hyperactivity Disorder

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04228094
Enrollment
33
Registered
2020-01-14
Start date
2020-08-10
Completion date
2022-05-09
Last updated
2022-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit-hyperactivity Disorder

Keywords

eHealth, evidence based medicine, machine learning

Brief summary

This is a 3-week open label, one group study to determine the agreement between the pharmacological treatment recommended by TDApp1 and the interventions recommended by relevant clinical practice guidelines.

Detailed description

Clinical practice guidelines (CPGP) allow optimizing medical decisions and health care based on the best evidence available. Nevertheless, CPGs have several limitations. First, many GPC are outdated shortly after their publication. Second, CPG recommendations are often not applicable to many patients treated in clinical practice. Most CPGs do not make recommendations for patients with a mild disorder or for complex patients with comorbiditie. Another limitation is that patients involvement in CPGs development is still poor. We aim to develop and assess TDApp1: an eHealth tool to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder. A 3-week, one group, open label study will be conducted. Fifty-five patients aged 6-65 with ADHD will use TDApp1. The therapeutic recommendations made by the TDApp1 and by relevant CPG will be compared. Concordance in the recommendations will be studied. Effectiveness, safety, changes in physical activity and satisfaction will be investigated.

Interventions

OTHERTDApp1: an eHealth intervention

TDApp1 is a tool that uses GRADE heuristics to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder

Sponsors

Universitat de Girona
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Years to 65 Years

Inclusion criteria

* Male and female patients ages 6-65 * A diagnosis of DSM-V ADHD based on clinical assessment

Exclusion criteria

* Patients under adequate therapeutic treatment or requiring minor adjustments * Patients lacking an electronic device (mobile phone, tablet,...) with internet access

Design outcomes

Primary

MeasureTime frameDescription
Treatment recommended/prescribed4 daysTreatment recommended/prescribed consists on the treatment recommended to the patient with ADHD by TDApp1 and the actual treatment prescribed by the investigator to this patient.

Secondary

MeasureTime frameDescription
Patient/parent satisfaction with TDApp13 weeksThe satisfaction of the patients or their parents with the educational material provided, and the usability and simplicity of TDApp1. This outcome will be collected by means of visual analogic scale that has been developed for this study. Score ranges from 1 to 9. Higher scores indicate greater satisfaction.
ADHD symptom severity3 weeksADHD symptom severity will be assessed with the self-rated, 18-item, DSM V (in children and adolescents) or IV-TR (in adults) -based Rating Scale. Total score ranges from 0 to 54. Higher total scores indicate greater illness severity.
Patient/parent satisfaction with the participation in the health decision-making process3 weeksSatisfaction of the patients or their parents with their participation in the health decision-making process. This outcome will be collected by means of visual analogic scale that has been developed for this study. Score ranges from 1 to 9. Higher scores indicate greater satisfaction.
Patient/parent satisfaction with the treatment prescribed3 weeksSatisfaction of the patients or their parents with the prescribed treatment. This outcome will be collected by means of visual analogic scale that has been developed for this study. Score ranges from 1 to 9. Higher scores indicate greater satisfaction.
Physical activity3 weeksThe physical activity will be measured by means of ActiGraph wGT3X-BT that records continuous physical activity and sleep/wake information.
Adverse events3 weeksThe incidence of adverse events will be collected by means of a questionnaire

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026